SlideShare a Scribd company logo
1 of 91
Download to read offline
Oral Mucosal Lesions
Presented by: Dibya Falgoon Sarkar (Dept. of Oral & Maxillofacial Surgery)
Contents
According to Burket oral mucosal lesions can be
broadly classified into:
 Red and white lesions
 Pigmented lesions
 Ulcerative, vesiculous and bullous lesions
Red and white lesions
 Infectious diseases:
1. Oral candidiasis
2. Oral hairy leukoplakia
 Premalignant disorders:
1. Oral leukoplakia and
erythroplakia
2. Oral submucous fibrosis
 Immunopathologic diseases:
1. Oral lichen planus
2. Lichenoid reactions
3. Lupus erythematosus
 Toxic reactions:
1. Tobacco pouch keratosis
2. Nicotinic stomatitis
 Reactions to mechanical
trauma:
1. Morsicatio
2. Frictional keratosis
 Others:
1. Benign migratory glossitis
2. Leukoedema
3. White sponge nevus
Oral Candidiasis (Thrush)
 Usually caused by the normally present Candida albicans which
becomes pathogenic because of altered host defense system.
Systemic factors Local factors
Diabetes , advanced systemic
disease
Use of dentures
Xerostomia- Drugs or radiation Reduced vertical dimension
Sjogren syndrome Overuse of antibiotic
mouthrinses
HIV infection & AIDS Lip-licking habit
Systemic antibiotic,
corticosteroid therapy
Classification of oral candidiasis
Primary oral candidiasis Secondary oral candidiasis
Pseudomembranous HIV-AIDS
Erythematous Familial chronic
mucocutaneous disease
Chronic plaque like DiGeorge syndrome
Denture stomatitis Candidiasis endocrinopathy
syndrome
Angular chelitis
Median rhomboid glossitis
Hyperplastic
Clinical presentations of oral candidiasis
Angular cheilitis Median rhomboid glossitis
Denture stomatitis HyperplasticPseudomembranous
Erythematous
Differential diagnosis
 Leukoplakia- A leukoplakia will always remain adherent to the
mucosa on rubbing. Candidiasis generally presents as
pseudomembrane
 Oral lichen planus- Generally presents as a reticular
striae(Wickham’s striae) and is adherent on rubbling. Often presents
with a burning sensation
 Secondary syphilis- Generally associated with a primary chancre
over site of inoculation
 Chemical/ heat burns
Diagnosis and treatment
 Investigation- Tissue biopsy stained with PAS stain/ KOH mount, Fungal
culture
 Treatment-(according to Marx & Stern)
1. Mild forms: Clotrimazole oral solution 5ml 3-4times daily for 2 weeks
2. Chronic well established: Nystatin oral suspension (1lacU/ml, 5ml, 4 times
daily) along with Clotrimazole troches (10mg, 5times daily)
Refractory forms : Fluconazoles (100mg capsules once daily, 2 weeks)
3. Disseminated forms: Amphotericin B i.v. with D5 solution at a rate of 0.2-0.7
mg/kg/day. But it can lead to nephrotoxicity
Oral hairy leukoplakia
 Oral hairy leukoplakia is the second
most common HIV-associated oral
mucosal lesion
 Associated with low CD4 T– lymphocyte
count
 Etiology- Epstein-Barr virus
 Prevalance- Prior to HAART era it was
around 25%
In AIDS patients it is around 80%
 Male> Female
 Prevalent in smokers
Clinical features, Diagnosis,
Treatment
 Site predilection- Lateral
borders of tongue
 Vertical white folds which
cannot be scraped off
 Asymptomatic condition
 Diagnosis- Biopsy
 Treatment- Antiviral
medication
Premalignant disorders
 Premalignant lesions:
 Oral leukoplakia
 Erythroplakia
 Reverse smoker’s palate
 Premalignant conditions:
 Oral submucous fibrosis
 Oral lichen planus
Oral leukoplakia
 Oral leukoplakia is defined as a white plaque of questionable risk having
excluded other known diseases or disorders that carry no risk for cancer
 Etiology: Smoking, use of tobacco products, alcohol abuse which cause genetic
changes in the oral mucosa
 Prevalence- 2.6%
 Mean age- 30-50 years
 Sex predilection: Men > Women
 Found in all oral sites. High-risk sites for
malignant transformation:
1. Floor of Mouth
2. Lateral borders of tongue
Types of oral leukoplakia
Homogenous Nonhomogeneous
White, well-demarcated plaque with identical
pattern throughout the entire lesion
• Presents as patches/plaques intermingled
with red elements
• Often termed as erythroleukoplakia/ speckled
leukoplakia
• Increased chances of malignant
transformation
Classification and Staging of Oral
Leukoplakia
Van der Waal et al., Journal of Oral oncology (2000)
 L (size of leukoplakia)
 L1: Size of single/ multiple leukoplakias together ≤ 2cm
 L2: Size of single/ multiple leukoplakias together 2-4cm
 L3: Size of single/ multiple leukoplakias together ≥4cm
 P (pathology)
 P0: No epithelial dysplasia
 P1: Distinct epithelial dysplasia present
 Staging:
 Stage I: L1Po
 Stage II: L2Po
 Stage III: L3Po or L1/L2P1
 Stage IV: L3P1
Management of oral leukoplakia
 Prognosis of leukoplakia patients is decided by:
1. Size of lesion
2. Homogeneous/non-homogeneous pattern
 According to Burket, lesions <200sq.mm shows better prognosis
 Cryotherapy can be used by it has limitations with depth control
 Laser surgery and fulguration is widely used to eradicate
leukoplakia and erythroplakia but tissue specimen for biopsy is
not available.
 According to Marx & Stern, leukoplakias which are graded as
moderately dysplastic/ carcinoma in-situ are managed with
surgical excision with 1cm margin regardless of size
According to van der Waal et al
Provisional clinical diagnosis
of leukoplakia
Elimination of possible cause
(2-4 weeks observation)
No possible cause
(Definitive clinical diagnosis)
Good response
No response
(Definitive clinical diagnosis) Biopsy
Definable lesion
• Management
accordingly
No definable lesion
Dysplasia/No dysplasia
Definable lesion
• Management
accordingly
• Treatment/ Observation
• Follow-up
Proliferative verrucous leukoplakia
 PVL is a field cancer phenomenon by which clinically normal-appearing oral
mucosa slowly transforms through advancing stages of clinical leukoplakia,
verrucous hyperplasia/ carcinoma, and then into invasive SCC
 More common in older women(4:1)
 Lower gingiva is a predilection site
 Most patients(78%) are usually non smokers
 High recurrence rate
 High malignant potential
 Increased correlation with oral Candida
infection
Diagnostic work-up &
Management of PVL
 Diagnosis mainly dependent on biopsy
 Principles of PVL excisions differ from other leukoplakias:
1. Clear all peripheral margins
2. Areas of excision often cover large surfaces and thus split-
thickness skin graft may be necessary after excision
 Chemoprevention with fluconazole oral suspension and
selenium(100microgram daily)
 Literature shows bad prognosis in laser treated PVL cases
Erythroplakia
 The term erythroplakia is used analogously to
designate lesions of oral mucosa that present
as red areas and cannot be diagnosed as any
other definable lesions (WHO, 1994)
 Rare premalignant lesion with a prevalence of
0.09% (Acc. to Shafer & Waldron)
 Age predilection: 6th-7th decades of life
 Male: Female - 1:1
 Site: Common in soft palate, buccal mucosa
and floor-of-mouth
 Aetiology: Same as those associated with
squamous cell carcinoma
Erythroplakia
 Rare lesion with a malignant
transformation rate of 26.3%
(Acc. To Reddi & Shafer’s study)
 Treatment : Observation for 1-2
weeks following elimination of
irritants. Complete excision of
the lesion with clear margins
down to the submucosal level is
the treatment of choice
 Recurrence rate <5% (Acc. To
Burket)
Differential diagnosis of red lesions of
oral mucosa:
1. Mycotic infections
• Erythematous candidiasis
• Denture stomatitis
• Histoplasmosis
2. Bacterial infections
• Tuberculosis
3. Mucosal diseases
• Pemphigus, pemphigoid
• Atrophic lichen planus
• SLE
4. Others
• Kaposi sarcoma
• Haemangioma
• Amelanotic melanoma
Oral submucous fibrosis
 Oral submucous fibrosis (OSF) is a collagen disorder commonly
seen in the Indian subcontinent
 First described by Schwartz in 1952
 Pindborg et al. found a prevalence of 0.2~0.5% in India
 Sex predilection: 5% prevalence in women & 2% in men
 Areca nut (the fruit of the Areca catechu) commonly known as
betel nut or supari, plays a crucial dual role in the etiology of OSMF
 The attendant trismus is a result of juxtaepithelial hyalinization and
secondary muscle involvement (i.e., muscular degeneration and
fibrosis)
 Malignant transformation has been noticed in 3-7.6% of cases
Pathogenesis of OSMF
Areca nut
Arecoline
(5-7%)
Tannins
(11-26%)
Alkaloids
(0.15%-0.6%)
Fibroblast
proliferation
Stimulates collagen
synthesis
Collagen fibrils resistant
to collagenase
Clinical features and staging
 One of the following characteristic must
be present :
1. Palpable fibrous bands
2. Mucosal texture feels tough and
leathery
3. Blanching of mucosa together with
histologic features consistent with
OSMF
4. Differential diagnosis: Scleroderma
(Widening of PDL spaces present along
with skin manifestations)
According to Khanna-Andrade article
Stage Clinical features Histology
Group I • The common initial
symptom was a burning
sensation in the mouth.
• Excessive salivation
• The mouth opening was
normal in all cases.
• fine fibrillar collagen
network was seen to be
interspersed with marked
edema. Blood vessels were
dilated and congested
• epithelium was essentially
normal and
nonkeratinized, with
occasionally some hy-
perplasia
Group II • Interincisal openings of
26-35 mm.
• The soft palate and faucial
pillars were the areas
primarily affected. The
buccal mucosa ap- peared
mottled and marble-like
• Juxtaepithelial hyalini-
zation was seen with the
collagen present as
thickened but separate
bundles.
• Flattening or shortening of
the epithelial rete pegs
was evident with varying
degrees of keratinization
Stage Clinical features Histology
Group III: moderately advanced
cases
• Trismus was evident, with an
inter- incisal opening of 15-
25 mm
• Vertical fibrous bands could
be palpated in the premolar
area.
• Juxtaepithelial hyalini- zation
was present. Thickened
collagen bundles were
faintly discernible, separated
by very slight, residual
edema
• Muscle fibers were seen to
be interspersed with
thickened and dense
collagen fibers.
Group IVa • Trismus was severe with an
interincisal opening of 2-15
mm.
• The fauces was thickened,
shortened, and firm to
palpation, with the tonsils
compressed between the
fibrosed pillars.
• Shrunken uvula
Collagen was hyalinized as a
smooth sheet eliminating all
evidence of individual bundles.
Extensive fibrosis had
obliterated the mucosal blood
vessels and eliminated the
melanocytes, a feature which
explained the clinically
observable loss of pigmentation
Group IVb • advanced cases with
premalignant and malignant
changes
Management of OSMF
 Actively discourage patients from
consuming areca nut and other
chronic irritants such as hot and spicy
foods
 Well balanced diet with vitamin A &
B-complex substitutes
 Wherever possible we extract the
third molars
 Group I & II patients are put on
conservative therapy and active
physiotherapy
 Group III & IV patients are treated by
surgical intervention
Conservative therapy in OSMF
 Physical therapy:
1. Physical exercise
2. Microwave diathermy
 Medical therapy:
 Modulators of inflammation:
1. Corticosteroid
2. Interferon gamma
3. Placental extracts
 Modulators for vascularity:
1. Pentoxiphylline
2. Nylidrin
 Fibrinolysis:
1. Hyaluronidase
2. Collagenase
 Nutritional support and
antioxidants:
1. Beta-carotene
2. Lycopene
3. Vitamins
 Ayurvedic treatment:
 Turmeric
 Tea pigments
Conservative therapy in OSMF
 Corticosteroid therapy: Submucosal injections of triamcinolone
acetonide (40 mg) injected into the faucial pillars, retromolar area,
and buccal mucosa. On average, a dose of 150-200 mg of local
submucosal corticosteroid injection was given in divided doses at
10-day intervals for a period of 2-3 months.
 Hyaluronidase(1500 I.U)- 0.5ml injected intralesionally twice a
week for 10 days
 Placental extract (Placentrex)- 2ml intralesional once a week
along with iodine and vitamin B complex
Surgical management
 Rationale: Incision or surgical release of fibrous bands followed by forceful
opening of mouth, and covering the surgical defects using various flaps
and biosynthetic materials
 In some cases we may need temporalis myotomy and bilateral
coronoidectomy
Extraoral flaps Intraoral flaps Microvascular Alloplasts
Split thickness
skin grafts
Tongue flap ALT flap Collagen
membrane
Temporalis
muscle/ fascia
pedicled flap
Palatal island flap Radial forearm
free flap
Artificial dermis
Nasolabial flap Buccal fat pad
Amnion graft
Review of literature
 Khanna & Andrade found disappointing results with split thickness
skin grafting as they found marked shrinkage. They advocated
bilateral palatal flaps.
 Borle & Borle also encountered disappointing results with skin
grafts. They used tongue flaps. But OSF patients show tongue
involvement in 38% cases and post op morbidities are more with
tongue flaps
 Andrade et al. and Mehrotra et al. concluded that nasolabial flaps
cannot extend adequately to cover the raw area and they also cause
facial scars
 Yeh et al. used pedicled buccal fat pad as it provided excellent
function without deteriorating esthetics
Verrucous carcinoma
 Verrucous carcinoma is a distinct low grade
variant of squamous cell carcinoma of oral
cavity
(According to Oral & maxillofacial surgery clinics-
2006)
 First identified by Ackerman in 1948.
 Rare tumor representing 3-4% of all oral
carcinomas
 Etiology- High incidence associated with use of
tobacco products
 16-51% of oral VCs are found in persons
without tobacco habits
 HPV is thought to be one of the causative agent
Clinical presentation of verrucous
carcinoma (VC)
 True VCs are slow-growing, painless,
broad-based wart-like papillary lesion
 Site: buccal mucosa (60% cases), Gingiva
(30%)
 Male predilection seen
 Age: Older than 50 years
 Shows high propensity of local invasion
rather than metastatic spread
 Evidence of osseous invasion has been
found
 Inflammatory regional lymph nodes
may be seen in some cases
Treatment of Verrucous
Carcinomas
 Excision to a depth of full thickness of mucosa is the treatment of choice
for oral VCs
 According to Marx & Stern excisional depth:
1. Buccal mucosa: Upto buccinator fascia
2. Gingiva: Upto a supraperiosteal plane
3. Posterior and floor of mouth lesions are excised with a 2cm margin
 Unlike squamous cell carcinomas VCs shows less radiosensitivity
 Transformation of VCs into SCCs have been seen after radiation therapy
 Recurrance rate: 26-57%
Oral lichen planus (OLP)
 Lichen planus is a T-cell mediated
autoimmune interface disease in
which the basal cell layer of
mucosa and/or skin is attacked
 Prevalence varies from 0.5-2.2%
 Women more commonly affected
 Mean age at the time of
diagnosis: Approx. 55yrs
 Premalignant condition
 Malignant transformation
potential 0.3-3%
 Cutaneous lesions: 15% cases
Clinical types of OLP
 Reticular type:
 Characterised by Wickham’s
striae of lacy, white interlacing
lines
 Most common in buccal mucosa
 Asymptomatic
 Papular type: Clinically
characterised by small white
dots which intermingle with the
reticular pattern
 Plaque type: Homogeneous
well-demarcated white plaque,
asymptomatic
Clinical types of OLP
 Erosive/atrophic type:
 Characterised by intense pain and
mucosal inflammation
 Presents as desquamative
gingivitis
 Ulcerative type:
 Most disabling form of OLP
 Fibrin coated ulcers surrounded
by erythematous zones and white
striae in periphery
 Bullous type: Presents as bullous
lesions surrounded by Wickham’s
striae
WHO diagnostic criteria for OLP (1978)
 Clinical criteria
1. Presence of white papules, anular, reticular, plaque-like lesions,
gray-white lines radiating from the papules
2. Presence of a lace-like network of slightly raised gray-white lines
(reticular type)
3. Presence of atrophic lesions with/without erosions may also have
bulla
WHO diagnostic criteria for OLP (1978)
 Histologic criteria
1. Presence of thickened orthokeratinised/ parakeratinised layers in
sites that are normally keratinised
2. Presence of Civatte bodies in basal layer, epithelium and superficial
part of connective tissue
3. Presence of a band-like zone of cellular infiltration in the superficial
connective tissue, consisting mainly lymphocytes
4. Signs of liquefaction degeneration in basal layer
Differential Diagnosis of OLP
 Papules/ reticular components have to
be present in order to establish correct
clinical diagnosis
 Differential diagnosis:
1. Discoid lupus erythematosus: Presents
with hyperkeratinisation, striae abruptly
terminate against a sharp demarcation
2. Pemphigus: Ulcerative type OLP have
same presentation
3. Leukoplakia
4. Oral candidiasis
Management of OLP
 Reticular and plaque forms do not require treatment other than
reassurance and follow-up
 Milder forms of erosive type are managed with topical
corticosteroids like clobetasol propionate/1% triamcinolone paste
 Topical application of cyclosporine, tacrolimus and retinoids have
been suggested as second-line of treatment
 Systematic corticosteroid therapy with oral prednisolone may be
used in extensive cases. But steroids have their side-effects
Short-term effects Long term effects
Hypertension, hyperglycaemia,
infections, peptic ulcer,
hypernatremia
Muscle wasting, delayed wound
healing, osteoporosis, cataracts
Systemic corticosteroid therapy protocols
Regimen I Regimen II Regimen IIIA Regimen IIIB
Oral Prednisolone
1.5mg/kg/day for 2
weeks followed by
tapering by 20mg/day
each week until a 20mg
/day dose is reached.
The dose is followed for
1month followed by
10mg/day for 3 months,
followed by 5mg every
other day for 6 months
Oral prednisolone 100-
120 mg/ day for 2
weeks after which the
drug is stopped
abruptly
• Disadv: Frequent
exacerbations
Oral prednisolone 100-
120 mg/ day for 2
weeks
• A tapering schedule
reduces prednisone
by 20mg/day each
week until lowest
possible level is
reached without
exacerbating the
disease
• Resistant
pemphigus cases
Oral prednisolone 100-
120 mg/ day for 2
weeks
• A tapering schedule
reduces prednisone
by 20mg/day each
week until a level is
reached at which
the disease is
exacerbated
• Combined with
other
immunosuppressive
drugs to reduce side
effects
Preferred in Steven
Johnson syndrome
Useful in patients with
life long steroid need
Useful regimen in
patients who cannot
tolerate high dose
steroids
Drug-induced Lichenoid Reactions
 Lichenoid reactions represent a family of lesions
with different etiologies with a common clinical
and histologic appearance
 Etiology and pathogenesis: DILRs resemble a
delayed hypersensitivity reaction where the
drugs and their metabolites have the capability
to act as haptens and trigger lichenoid reactions
 Clinically appears similar to cutaneous LP and
may be pruritic
 DILRs are not life-threatening like Toxic
epidermal necrolysis
Common drugs
ACE inhibitors
Antimalarials
Penicillin group
Gold and heavy metals
Sulphonamides
OHA and OCPs
Rifampicin
Drug-induced Lichenoid
Reactions
 Management of drug-induced lichenoid reactions:
 Discontinuation of the drug and symptomatic treatment with topical
steroids
 Patients must be cautioned of future use of same drugs
Systemic Lupus Erythematous
 SLE is an autoimmune disorder in which antigen-
antibody complexes become entrapped in the
capillaries of most organs. These complexes initiate
the complement cascade and inflammation
 Marked female predilection (90%) seen
 Peak incidences between 20-40 years
 Most characteristic signs-
1. Malar butterfly rash
2. Positive serum ANA test
 Pathogenesis: Development of autoantibodies
against native double stranded DNA. There marked
depletion of complement proteins
ACR diagnostic criteria for SLE
1. Serositis
2. Oral ulcers
3. Arthritis
4. Photosensitivity
5. Blood disorders- Lymphopenia, leukopenia, thrombocytopenia
6. Renal disorders- 0.5g/2h protonectin, cellular casts in urine
7. Anti-nuclear antibody positivity
8. Immunologic disorders
9. Neurologic disorders- seizure, psychosis
10. Malar rash
11. Discoid rash
 At least 4 of these 11 criteria must be present before definitive diagnosis of SLE can be
made along with a positive serum ANA test
 Oral ulcers are red shallow ulcers commonly found in palate and marginal gingiva
Differential diagnosis of SLE
1. Erythema multiforme
2. Discoid lupus erythematosus
3. Rheumatoid arthritis
4. Drug-induced lupus syndrome:
 Males are equally affected
 No neurologic/renal components
 Anti- native DNA antibodies not
present
 Symptoms improve on stoppage of the
drug
Treatment of SLE
 Mild forms of SLE are managed by supportive care.
NSAIDS are given in mild flare-ups. Hydroxychloroquine 400mg orally
is used to alleviate symptoms
 Severe forms with multi-organ involvement are managed with
systemic prednisone( systemic corticosteroid therapy IIIA & IIIB)
Mycophenolate and cyclophosphamide may be added to these
regimen to reduce the steroid requirement.
Topical therapy for Oral lesions of
SLE
Drugs Direction for use
0.05% Clobetasol gel Place on affected area(s) 2 times/ day
for 2 weeks
Triamcinolone acetonide 5mg/ml Intralesional injection
Topical clotrimazole troches (10mg) Dissolve in mouth 5 times/day for 10
days
Chlorhexidine rinse (0.12%) Swish and spit 10ml twice daily until
lesions resolve
Adapted from Brennan et al.
Discoid lupus erythematosus
 Also known as chronic cutaneous lupus
erythematosus
 Immune-based disease primarily targets skin and to
lesser degree, mucosa.
 Lesions show similar characteristics and site
predilection like that of SLE
 Differential diagnosis:
1. SLE (No ANAs, hypocomplementia found)
2. Psoriasis 3. Skin TB 4. Leprosy
 Treatment: Topical corticosteroids and preventive
measures are taken in mild forms
Severe forms are treated with systemic steroid
regimens I & II
Nicotinic stomatitis/ Smoker’s palate
 Smoker’s palate initially presents as
erythematous irritation and later transforms into
a whitish palatal mucosa reflecting a
hyperkeratosis
 Reds dot can be observed representing inflamed
orifices of accessory salivary gland ducts which
can be enlarged and metplastic
 Etiology and pathogenesis:
 Seen in cigar and pipe smokers but not in
cigarette smokers
 Caused due to a combined effect of heat and
tobacco products,
 Not a premalignant lesion
 Treatment: Cessation of smoking
Leukoedema
 Leukoedema is a white and veil-
like alteration of the oral mucosa
 Asymptomatic condition with no
malignant potential
 Etiology is not clear
 Unlike leukoplakia, it is more
diffuse and temporarily
disappears on stretching
 Requires no treatment
White sponge nevus
 Rare autosomal dominant disorder
 Caused due to mutation of genes coding for
epithelial keratin formation
 Clinical features:
• White lesions with elevated and irregular surface
• Commonly seen in buccal mucosa
 Histologically spinous epithelial cells show
marked intracellular edema and are nondysplastic
 Management: Benign, asymptomatic
Benign Migratory Glossitis/
Geographic tongue
 Annular lesion affecting the dorsum and margins of
tongue
 Unknown etiology, equal gender distribution
 Prevalence 1-2.5% of all oral lesions
 Clinical features:
 Circumferentially migrating lesions with erythematous
areas of depapillated tongue
 Peripheral zones are white and elevated
 Aggravates in periods of stress
 Mostly asymptomatic
 Self healing lesions
 Symptomatic patients are given topical anesthetics
Pigmented lesions of oral mucosa
 Hairy tongue
 Malignant melanoma
 Haemochromatosis
 Peutz-Jegher’s syndrome
 Melasma
 Amalgam tattoos
 Endogenous pigmentation
Hairy tongue
 Etiology is unkown in most cases
 Probable causes are:
1. Poor oral hygiene
2. Use of antibiotics/ immunosuppressant drugs
3. Therapeutic radiation
4. Excessive alcohol consumption
5. Smoking habits
 Clinically presents as an impaired desquamation of the
filiform papilla which leads to elongated papilla over dorsum
of tongue
 Pigmentation mainly comes from the oral microflora
 Patients experience physical discomfort
 Treatment: Use of tongue scrappers
Malignant melanoma
 Melanomas comprise of a rare group of aggressive, malignant
neoplasms which are mainly found in skin of white people
 Oral mucosal melanomas comprise of 0.2-8% of all melanomas
diagnosed, commonly found in males more than 45 years age
 Metastasis is predominantly via haematogenous routes
 Site: Most common site is palate followed by the maxillary
gingiva
Nevus Melanoma
Symmetry Asymmetry
Borders regular Irregular borders
Uniform color Color variegation
Diameter static Diameter enlargement (>6mm)
Color stable Evolution to darker pigment
Clinical types of Oral Melanomas
Superficial spreading
• Most common
between 40-60 years
age
• Initiallly looks like a
nevus but later
develop irregular
border and odd
shape
• This radial growth
pattern later changes
Acral lentiginous
• Rarely found in oral
cavity
• Characterised by a
flat papular lesion
with areas of
nodularity (Vertical
component
Nodular melanoma
• Most common between
50-70 years of age
• Common in men
• Shows vertical growth
• Poor prognosis
• Occasionally present as
a flesh colored
mass,amelanotic
melanoma
Breslow’s measurement of tumor
thickness
Thickness (mm) Risk of recurrence
<0.76 Low risk
0.76-1.50 Low to intermediate risk
1.51-3.99 Intermediate to high risk
>4.00 High risk
Indicators of poor prognosis:
• Surface ulceration
• High mitotic index
• Absence of lymphocyte infiltrations
• Distant/ regional metastasis
 Five year survival rate in patients with metastatic
melanoma is <15%
Treatment of oral melanomas
 According to Marx & Stern wide local excision with 3-5cm margins is
the treatment of choice. Neck dissection is to be done in cases with
cervical lymph node metastasis
 According to Burket adjuvant chemotherapy with alpha 2B interferon is
approved in cutaneous melanoma cases with >4mm thickness
 Use of adjuvant radiotherapy is a matter of debate
 8 years survival rate is about 20%
 Lungs is the most common site of metastasis followed by skin
Oral Mucosal Lesions- Part II
Presented by: Dibya Falgoon Sarkar (Dept. of Oral & Maxillofacial Surgery)
Ulcerative, vesicular and bullous lesions
Frequently used terms
1. Vesicles Small blisters containing clear fluid that are less
than 1cm in diameter
2.Bullae Elevated blisters > 1cm in diameter
3. Erosions Red lesions caused by rupture of vesicles/bullae or
by thinning of the skin
4. Ulcers A well-circumscribed, depressed lesion with an
epithelial defect
5. Pustules Blisters containing yellowish purulent matter
6. Papules Lesions raised above skin/ mucosa < 1cm in
diameter
7. Plaques Raised lesions > 1cm in diameter
 We can broadly divide these type of lesions into:
1. Acute multiple ulcers:
• Herpes simplex virus
• Varicella-zoster
• Erythema multiforme
• Stevens- Johnson syndrome & Lyell disease
• Necrotizing ulcerative gingivitis & periodontitis
2. Recurring oral ulcers:
• Recurrent apthous stomatis
• Behcet syndrome
3. Chronic multiple ulcers:
• Pemphigus vulgaris
• Pemphigoid
4.Single ulcers: mostly traumatic ulcers
Ulcerative, vesicular and bullous lesions
Herpes simplex virus infections (HSV)
 HSV infections are caused by the Herpesviridae family.
Spreads via airborne/ direct contact.
 In general, infections above the waist are caused by HSV-
1 and below waist by HSV-2
 Pathogenesis: Primary lesion is caused by inoculation of
the virus in the oral mucosa, skin and eye with infected
secretions
 The virus then travels along the sensory neurons and
causes a chronic, latent infection in sensory ganglion
 Recurrent herpes occurs when HSV reactivates at latent
sites and travels centripetally to the mucosa/ skin
Clinical manifestations
of HSV infection
 Primary herpetic gingivostomatitis:
• Caused mostly in children and young adults
• Painful vesicular lesions on mucosal surfaces
• Febrile, cervical lymphadenopathy
• Lasts for 10 days and resolve on its own
 Herpetic whitlow:
• Occupational hazard among dentists
• Contracted from the infected patients
in the finger pads
 Recurrent herpes: Seen over keratinised
surfaces like palate and gingiva
Diagnosis & management of HSV
 Diagnosis:
• Immunoslot testing detects circulating viral antibodies
• Viral cultures and tissue biopsy are other alternatives
 Treatment:
• Self limiting disease which remains for 7-10 days
• Topical 5% Acyclovir cream is helpful reduce symptoms
• In extensive cases, oral Acyclovir 200mg five times for 10
days. Valacyclovir has more bioavailability
Differential diagnosis
1.Erythema mutiforme
2.Erosive lichen planus
3. Apthous ulcer
4. Pempigus vulgaris
Herpes Zoster virus infection
 Primary infection with varicella zoster virus
leads to varicella (chicken pox).
 Reactivation of latent virus in the dorsal root ganglia
of cranial nerves lead to herpes
zoster infection/shingles.
 Incidence: 1.5-3 cases per 1000 cases
 More common in older individuals (>75 years)
 Transmission usually by respiratory route.
 Incubation period: 1-2 weeks
 Postherpetic neuralgia is an uncommon sequelae
seen in older individuals.
Pathogenesis of Shingles and
Postherpetic Neuralgia
Clinical manifestations
 Primary VZV infection mostly occurs in first two
decades of life as maculopapular rash.
 HZI of skin occurs in adults and start with prodromal
symptoms like deep, burning skin sensation.
 Within 2-4 days vesicles are seen in a dermatomal
pattern unilaterally
 Oral & maxillofacial manifestations:
• Most commonly affects the ophthalmic div. of
trigeminal nerve
• Prodromal phase is characterised by burning mucosal
pain
• This is followed by appearance of clusters of 1-
5mm ulcers which heal within 14days
Diagnosis & Management of
HZV infections
 Oral swab for viral isolation using cell culture is best way for confirming
diagnosis. Real time PCR can also be used
 Treatment:
 Acyclovir (800mg five times a day)
 Valacyclovir (1000mg three times a days)
 Regimen shoud be started within 72hrs of onset
 Postherpetic neuralgia:
• First line of treatment is 5% lidocaine patch and topical capsaicin
• Second line of treatment is with pregabalin, opioid analgesics and TCAs
• Case reports suggest use of botulinum toxin in PHN
 Vaccination of older adults reduces incidence of HZ infections.
Ramsay-Hunt syndrome
 Uncommon complication of Herpes zoster
infection
 Involves the geniculate ganglion
 Clinical features:
 Bell’s palsy, vesicles of external ear and loss
of taste sensation in the anterior two thirds
of tongue
 Herpes zoster infections are more common
in immunocompromised individuals
Erythema multiforme (EM)
 Acute, self-limited, inflammatory mucocutaneous
disease.
 Commonly manifests in skin, oral mucosa
& genitalia
 Represents hypersensitivity reactions to
medications or infectious agents(e.g: Pneumonia,
HSV, mycoplasma)
 Two types: (Acc. To Burket)
1) Erythema multiforme minor- < 10% of
total body skin
1) Erythema multiforme major- More extensive skin &
mucosal involvement
Clinical findings
 EM generally affects individuals between
20-40 years
 Prodromal phase is characterised with
fever, malaise and headache, cough,
rhinorrhea
 Target/ iris lesions are pathognomonic
of EM
 Oral cavity lesions shows painful
erythematous ulcerations, lips show
haemorrhagic crusting
Management of EM
 Mild oral EM can be managed with systemic/ topical analgesics for
pain and supportive care since the disease is self-limiting
 More severe cases are manged with topical/ systemic corticosteroids
 Acyclovir may be added if HSV infection is suspected
 However, Marx & Stern contraindicates the use of steroids in EM
minor as they are saying use of steroids increase the chance of
infections
Stevens-Johnson Syndrome
 Also known as Erythema multiforme major
 Life threatening and debilitating hypersensitivity
 Characterised by an intense vasculitis due to a combined type III
& IV hypersensitivity
 Age: Less than 15 years
 Clinical features: Triad of oral, ocular and genital lesions
 SJS has an explosive onset and progress very rapidly
 Treatment:
 Emergency condition, requires intense supportive care
 Fluid resuscitation is required to prevent dehydration
 Systemic corticosteroids(IV methylprednisolone 500mg) along
antibiotics coverage and immunosuppressive drugs
 Silver diazine creams are applied locally, protection of eyes
Necrotising ulcerative gingivitis
and periodontitis
 Represents an acute ulcerative-
inflammatory condition of the
gingiva and periodontium
 Associated with polymicrobial
infections
 Strong association with immune
suppression, diabetes, debilitation,
smoking, stress, poor oral hygiene,
local trauma, etc.
 Etiology: Fusospirochaetal
microorganisms
 In presence of systemic illness NUG
and NUP can progress into cancrum
oris/ noma
Seven stages of ANUG -
Horning & Cohen
Stages
Stage I Necrosis of tip of papilla
Stage II Necrosis of entire papilla
Stage III Necrosis extending to marginal gingiva
Stage IV Necrosis extending to attached gingiva
Stage V Necrosis extending to labial & buccal mucosa
Stage VI Necrosis exposing alveolar bone
Stage VII Necrosis perforating skin of cheek
Clinical features
 Necrotising ulcerative gingivitis have a rapid
onset.
 First symptoms are excessive salivation, metallic
taste, sensitivity of gingiva.
 Disease rapidly progress into extremely painful
punched-out ulcers which starts from
interdental papilla.
 Differential diagnosis:
1. Primary herpetic gingivostomatitis
2. Desquamative gingivitis
3. Mucous membrane pemphigoid
 Laboratory tests: Gingival sulcular secretion
culture.
Treatment
 Management is directed toward supportive care, pain control and
identification of predisposing factors.
 Definitive treatment consists of gentle debridement to remove
plaque and debris under LA.
 Hydrogen peroxide is used for killing anaerobic microbes along with
chlorhexidine mouth wash.
 Beta lactams and Metronidazole are antibiotics of choice
 Patients must be tested for HIV
 Once the acute phase is over we perform scaling and root planing for
residual plaque removal.
 Periodontal surgery is needed to correct the periodontal defects.
Aphthous Stomatitis
 Also known as canker sores
 Pathogenesis: Believed to be
due to an immune-based
leukoclastic vasculitis
Types Clinical findings
Minor Most common, <1cm, lasts for 7-14 days, no scarring is seen,
occurs over free oral mucosa
Major >1cm, lasts for weeks, heals with scarring
Herpetiform <1cm, >10 ulcers, dispersed widely over oral mucosa
Severe Same as minor, but ulcers present continuously
Treatment of aphthous ulcers
 Minor aphthous ulcers are self-limiting and requires only
reassurance of the patient.
 Major aphthous ulcers are treated with a combination of antibiotics
and systemic steroids.
 Marx & Stern proposes three antibiotic regimens (2-6 months):
1. Erythromycin 250mg orally 4 times daily
2. Doxycycline 100mg orally once daily
3. Tetranydril elixir/ Magic mouth wash (Tetracycline 250mg+ 12.5 mg
Diphenhydramine HCl per 5ml of Kaopectate
 If these regimens fail we generally opt for systemic corticosteroid
regimen with prednisone.
Behcet syndrome
 Triad of recurring oro-genital ulcers and eye
involvement
 Occurs in young adults, male predilection seen
 Diagnostic criteria:
a) Recurrent oral ulcers: Aphthous type ulcers
which occur atleast 3 times in I year period
b) Plus 2 of the following:
1. Eye lesions: Uveitis, retinal vasculitis and
hypopyon
2. Skin lesions: Papulopustular genital lesions
3. Positive pathergy test
 Treatment: Systemic corticosteroid regimen I
or III with prednisone
Pemphigus vulgaris (PV)
 Pemphigus vulgaris falls in a group of
autoimmune, potentially life-
threatening disease.
 Characterized by blisters and erosions
of skin and mucous membranes due to
intraepithelial acantholysis.
 Etiology: Caused due to binding of
IgG autoantibodies to desmoglein 3 &
1( transmembrane adhesion
molecules) present on desmosomes.
 Incidence: 0.1-0.5 cases per 1 lacs per
year
Clinical manifestations of PV
 Classic lesion of PV consists of a thin-walled bulla arising on an otherwise
normal skin/ mucosa.
 These bullae rupture and continue to extend peripherally leaving areas of
ulcerated mucosa and denuded skin ( Lutz sign).
 Nikolsky sign: Pressure application on an apparently normal area of skin
results in formation of a new lesion.
 Oral lesions precede the lesions of skin
 Diagnosis:
1. Direct immunofluorescence
2. Indirect immunofluorescence
3. Biopsies are best done on intact vesicles < 24hrs old
Differential diagnosis of PV
1. Herpes simplex virus infections: Affects young children,
acute onset
2. Erythema multiforme: Acute nature, patient gives history
of taking medications in most cases, target lesions are seen
3. Recurrent aphthous stomatitis: Aphthous ulcers are
round and symmetrical. They tend to heal and recur. But in
pemphigus, the same lesions continue to extend
peripherally in a chronic nature.
4. Mucous membrane pemphigoid: Distinguished by
indirect immunofluorescence
Treatment of Pemphigus vulgaris
 Most important aspect is early diagnosis of the disease when lower
doses of medication can be used for shorter periods of time to control
the disease.
 High doses of systemic corticosteroids (Prednisone) are given in
dosages of 1-2mg/kg/day
 Adjuvant therapy to reduce the side-effects of steroids include
azathioprine, mycophenolate, etc.
 Rituximab is presently used though there are reports of high infection
rates.
Mucous Membrane Pemphigoid
 Chronic autoimmune subepithelial disease which primarily
affects mucous membranes
 Age: More than 50 years
 Female:Male : 2:1
 Etiology: Primary lesion of MMP occurs when
autoantibodies directed against proteins in the basement
membrane zone cause a subepithelial split and vesicle
formation.
 Conjuctiva is the second most common site after oral cavity.
 Corneal damage, symblepheron and blindness are common
ocular manifestations.
 Desquamative gingivitis is the most common oral lesion
Treatment of mucous membrane
pemphigoid
 Patients with mild oral disease are
treated with topical and
intralesional steroids
 Ophthalmologists must be
consulted for the management of
ocular manifestation
 Systemic steroid therapy regimen
I & III are used in severe cases
Cicatricial pemphigoid
with symblepheron
Management of patients on
Corticosteroid therapy who require
Major surgery
 Patients who regularly take corticosteroids develop adrenal
insufficiency due to depression of HPA axis.
 According to Hupp, Ellis & Tucker:
1. If the pateint is currently taking steroids:
 Use anxiety-reduction protocol.
 Monitoring of vitals before, during and after surgery.
 Instruct patient to double usual daily dose on day before, day of,
and day after surgery.
 On second post op day advise the patient to return to usual
dose.
Management of patients on
Corticosteroid therapy who
require Major surgery
 According to Hupp, Ellis & Tucker:
2. If the patient is not currently taking steroids but has received
atleast 20mg of hydrocortisone or equivalent for >2 weeks in
past one year,
 Use anxiety-reduction protocol
 Monitoring of vitals before, during and after surgery.
 Instruct the patient to take 60mg hydrocortisone on the day
before and the morning of surgery
 On the first 2 post op days, the dose should be dropped to
40mg and dropped to 20mg for 3 days thereafter. The
clinician can cease administration of supplemental steroids 6
days after surgery.
References
 Burket’s Oral Medicine
 Oral & Maxillofacial Pathology – Marx & Stern
 Oral & Maxillofacial Surgery Clinics of North America (2006 issue)
 Van der Waal et al., Journal of Oral oncology (2000)
 Khanna, Andrade: Oral submucous fibrosis : A new concept of
management: Report of 100 cases; IJOMS 1995
Oral mucosal lesions

More Related Content

What's hot

What's hot (20)

Chronic gingivitis
Chronic gingivitisChronic gingivitis
Chronic gingivitis
 
"GINGIVAL-ENLARGEMENT"
"GINGIVAL-ENLARGEMENT""GINGIVAL-ENLARGEMENT"
"GINGIVAL-ENLARGEMENT"
 
Cemento osseus dysplasia (Doctor Faris Alabeedi MSc, MMedSc, PgDip, BDS.)
Cemento osseus dysplasia (Doctor Faris Alabeedi MSc, MMedSc, PgDip, BDS.)Cemento osseus dysplasia (Doctor Faris Alabeedi MSc, MMedSc, PgDip, BDS.)
Cemento osseus dysplasia (Doctor Faris Alabeedi MSc, MMedSc, PgDip, BDS.)
 
Oral Submucous Fibrosis
Oral Submucous FibrosisOral Submucous Fibrosis
Oral Submucous Fibrosis
 
Oral squamous cell carcinoma
Oral squamous cell carcinomaOral squamous cell carcinoma
Oral squamous cell carcinoma
 
Acute apical-periodontitis.25.mar.2013
Acute apical-periodontitis.25.mar.2013Acute apical-periodontitis.25.mar.2013
Acute apical-periodontitis.25.mar.2013
 
case history in prosthodontics
case history in prosthodonticscase history in prosthodontics
case history in prosthodontics
 
Red lesion of oral mucosa
Red lesion of oral mucosa Red lesion of oral mucosa
Red lesion of oral mucosa
 
Chronic periodontitis
Chronic periodontitisChronic periodontitis
Chronic periodontitis
 
ORAL VESICULOBULLOUS LESION
ORAL VESICULOBULLOUS LESIONORAL VESICULOBULLOUS LESION
ORAL VESICULOBULLOUS LESION
 
Oral White lesions
Oral White lesionsOral White lesions
Oral White lesions
 
oral submucous fibrosis
oral submucous fibrosisoral submucous fibrosis
oral submucous fibrosis
 
Oral Lichen Planus
Oral Lichen PlanusOral Lichen Planus
Oral Lichen Planus
 
principles of instrumentation of hand instruments
principles of instrumentation of hand instrumentsprinciples of instrumentation of hand instruments
principles of instrumentation of hand instruments
 
Intra oral examination
Intra oral examinationIntra oral examination
Intra oral examination
 
Mpds
MpdsMpds
Mpds
 
Dental mobility
Dental mobilityDental mobility
Dental mobility
 
Diagnosis of dental caries
Diagnosis of dental cariesDiagnosis of dental caries
Diagnosis of dental caries
 
Intra oral examination
Intra oral examinationIntra oral examination
Intra oral examination
 
Leukoplakia case presentation
Leukoplakia case presentationLeukoplakia case presentation
Leukoplakia case presentation
 

Similar to Oral mucosal lesions

Premalignant lesions and biopsy
Premalignant lesions and biopsyPremalignant lesions and biopsy
Premalignant lesions and biopsySujay Patil
 
POTENTIALLY MALIGNANT DISORDER
POTENTIALLY MALIGNANT DISORDERPOTENTIALLY MALIGNANT DISORDER
POTENTIALLY MALIGNANT DISORDERAnweshaBiswas13
 
Precancerous lesions of oral cavity
Precancerous lesions of oral cavityPrecancerous lesions of oral cavity
Precancerous lesions of oral cavityDr. Bibina George
 
Premalignant lesions and conditions
Premalignant lesions and conditionsPremalignant lesions and conditions
Premalignant lesions and conditionsakshay shete
 
Diseases of oral cavity and ludwig’s angina ug,18.07.16 dr.davis thomas
Diseases of oral cavity and ludwig’s angina ug,18.07.16  dr.davis thomasDiseases of oral cavity and ludwig’s angina ug,18.07.16  dr.davis thomas
Diseases of oral cavity and ludwig’s angina ug,18.07.16 dr.davis thomasophthalmgmcri
 
Diseases of oral cavity and ludwig’s angina ug,18.07.16 dr.davis thomas
Diseases of oral cavity and ludwig’s angina ug,18.07.16  dr.davis thomasDiseases of oral cavity and ludwig’s angina ug,18.07.16  dr.davis thomas
Diseases of oral cavity and ludwig’s angina ug,18.07.16 dr.davis thomasophthalmgmcri
 
Neoplastic transformation of oral lichen
Neoplastic transformation of oral lichenNeoplastic transformation of oral lichen
Neoplastic transformation of oral lichenAparna Srivastava
 
Oral Potentially Malignant Disorders
Oral Potentially Malignant DisordersOral Potentially Malignant Disorders
Oral Potentially Malignant DisordersShreyaSinha676143
 
Premalignant lesion
Premalignant lesionPremalignant lesion
Premalignant lesiondhuha khalid
 
precancerous lesions in oral cavity
precancerous lesions in oral cavityprecancerous lesions in oral cavity
precancerous lesions in oral cavitysuleman khan
 
Oral cavity & neck
Oral cavity & neckOral cavity & neck
Oral cavity & neckAnkita Singh
 
Pre-malignant Lesions of Oral mucosa.pptx
Pre-malignant Lesions of Oral mucosa.pptxPre-malignant Lesions of Oral mucosa.pptx
Pre-malignant Lesions of Oral mucosa.pptxDr Safika Zaman
 
Carcinomatongue 150622043025-lva1-app6891
Carcinomatongue 150622043025-lva1-app6891Carcinomatongue 150622043025-lva1-app6891
Carcinomatongue 150622043025-lva1-app6891Liju Rajan
 
Scribd doc
Scribd docScribd doc
Scribd docshwerit
 

Similar to Oral mucosal lesions (20)

Pre cancerous lesions & conditions
Pre cancerous lesions & conditionsPre cancerous lesions & conditions
Pre cancerous lesions & conditions
 
Premalignant lesions and biopsy
Premalignant lesions and biopsyPremalignant lesions and biopsy
Premalignant lesions and biopsy
 
POTENTIALLY MALIGNANT DISORDER
POTENTIALLY MALIGNANT DISORDERPOTENTIALLY MALIGNANT DISORDER
POTENTIALLY MALIGNANT DISORDER
 
Premalignant condition
Premalignant conditionPremalignant condition
Premalignant condition
 
Precancerous lesions of oral cavity
Precancerous lesions of oral cavityPrecancerous lesions of oral cavity
Precancerous lesions of oral cavity
 
Premalignant lesions and conditions
Premalignant lesions and conditionsPremalignant lesions and conditions
Premalignant lesions and conditions
 
Diseases of oral cavity and ludwig’s angina ug,18.07.16 dr.davis thomas
Diseases of oral cavity and ludwig’s angina ug,18.07.16  dr.davis thomasDiseases of oral cavity and ludwig’s angina ug,18.07.16  dr.davis thomas
Diseases of oral cavity and ludwig’s angina ug,18.07.16 dr.davis thomas
 
Diseases of oral cavity and ludwig’s angina ug,18.07.16 dr.davis thomas
Diseases of oral cavity and ludwig’s angina ug,18.07.16  dr.davis thomasDiseases of oral cavity and ludwig’s angina ug,18.07.16  dr.davis thomas
Diseases of oral cavity and ludwig’s angina ug,18.07.16 dr.davis thomas
 
Neoplastic transformation of oral lichen
Neoplastic transformation of oral lichenNeoplastic transformation of oral lichen
Neoplastic transformation of oral lichen
 
Oral Potentially Malignant Disorders
Oral Potentially Malignant DisordersOral Potentially Malignant Disorders
Oral Potentially Malignant Disorders
 
Premalignant lesion
Premalignant lesionPremalignant lesion
Premalignant lesion
 
precancerous lesions in oral cavity
precancerous lesions in oral cavityprecancerous lesions in oral cavity
precancerous lesions in oral cavity
 
Oral cavity & neck
Oral cavity & neckOral cavity & neck
Oral cavity & neck
 
group_1_denta.pptx.ppt
group_1_denta.pptx.pptgroup_1_denta.pptx.ppt
group_1_denta.pptx.ppt
 
Lichen planus
Lichen planusLichen planus
Lichen planus
 
05
0505
05
 
Pre-malignant Lesions of Oral mucosa.pptx
Pre-malignant Lesions of Oral mucosa.pptxPre-malignant Lesions of Oral mucosa.pptx
Pre-malignant Lesions of Oral mucosa.pptx
 
Carcinomatongue 150622043025-lva1-app6891
Carcinomatongue 150622043025-lva1-app6891Carcinomatongue 150622043025-lva1-app6891
Carcinomatongue 150622043025-lva1-app6891
 
management of Oral leukoplakia by cryotherapy
 management of Oral leukoplakia by cryotherapy management of Oral leukoplakia by cryotherapy
management of Oral leukoplakia by cryotherapy
 
Scribd doc
Scribd docScribd doc
Scribd doc
 

More from Dibya Falgoon Sarkar

Surgical approaches for condylar fractures related to facial nerve injury: de...
Surgical approaches for condylar fractures related to facial nerve injury: de...Surgical approaches for condylar fractures related to facial nerve injury: de...
Surgical approaches for condylar fractures related to facial nerve injury: de...Dibya Falgoon Sarkar
 
Genioglossus muscle advancement and simultaneous sliding genioplasty in the m...
Genioglossus muscle advancement and simultaneous sliding genioplasty in the m...Genioglossus muscle advancement and simultaneous sliding genioplasty in the m...
Genioglossus muscle advancement and simultaneous sliding genioplasty in the m...Dibya Falgoon Sarkar
 
Corseting: A new technique for the management of diffuse venous malformations...
Corseting: A new technique for the management of diffuse venous malformations...Corseting: A new technique for the management of diffuse venous malformations...
Corseting: A new technique for the management of diffuse venous malformations...Dibya Falgoon Sarkar
 
More harm than benefit of perioperative dexamethasone on recovery following ...
More harm than benefit of perioperative  dexamethasone on recovery following ...More harm than benefit of perioperative  dexamethasone on recovery following ...
More harm than benefit of perioperative dexamethasone on recovery following ...Dibya Falgoon Sarkar
 
Validity of sentinel node biopsy in early oral and oropharyngeal carcinoma
Validity of sentinel node biopsy in early oral and oropharyngeal carcinomaValidity of sentinel node biopsy in early oral and oropharyngeal carcinoma
Validity of sentinel node biopsy in early oral and oropharyngeal carcinomaDibya Falgoon Sarkar
 
Naso-orbital-ethmoid (NOE) fractures: Management principles, options and rec...
Naso-orbital-ethmoid (NOE) fractures: Management principles, options  and rec...Naso-orbital-ethmoid (NOE) fractures: Management principles, options  and rec...
Naso-orbital-ethmoid (NOE) fractures: Management principles, options and rec...Dibya Falgoon Sarkar
 
Temporomandibular joint ankylosis and its management
Temporomandibular joint ankylosis and its managementTemporomandibular joint ankylosis and its management
Temporomandibular joint ankylosis and its managementDibya Falgoon Sarkar
 
Management of Impacted Third Molars
Management of Impacted Third MolarsManagement of Impacted Third Molars
Management of Impacted Third MolarsDibya Falgoon Sarkar
 
Paranasal sinus diseases and their management
Paranasal sinus diseases and their managementParanasal sinus diseases and their management
Paranasal sinus diseases and their managementDibya Falgoon Sarkar
 
Surgical Anatomy of Temporomandibular Joint
Surgical Anatomy of Temporomandibular JointSurgical Anatomy of Temporomandibular Joint
Surgical Anatomy of Temporomandibular JointDibya Falgoon Sarkar
 
Surgical Anatomy of Salivary Glands and its Applied aspects
Surgical Anatomy of Salivary Glands and its Applied aspectsSurgical Anatomy of Salivary Glands and its Applied aspects
Surgical Anatomy of Salivary Glands and its Applied aspectsDibya Falgoon Sarkar
 
Evolution of oral and maxillofacial surgery
Evolution of oral and maxillofacial surgeryEvolution of oral and maxillofacial surgery
Evolution of oral and maxillofacial surgeryDibya Falgoon Sarkar
 
Implants : An Overview, Biomechanics & Treatment Planning
Implants : An Overview, Biomechanics & Treatment PlanningImplants : An Overview, Biomechanics & Treatment Planning
Implants : An Overview, Biomechanics & Treatment PlanningDibya Falgoon Sarkar
 

More from Dibya Falgoon Sarkar (18)

Surgical approaches for condylar fractures related to facial nerve injury: de...
Surgical approaches for condylar fractures related to facial nerve injury: de...Surgical approaches for condylar fractures related to facial nerve injury: de...
Surgical approaches for condylar fractures related to facial nerve injury: de...
 
Genioglossus muscle advancement and simultaneous sliding genioplasty in the m...
Genioglossus muscle advancement and simultaneous sliding genioplasty in the m...Genioglossus muscle advancement and simultaneous sliding genioplasty in the m...
Genioglossus muscle advancement and simultaneous sliding genioplasty in the m...
 
Corseting: A new technique for the management of diffuse venous malformations...
Corseting: A new technique for the management of diffuse venous malformations...Corseting: A new technique for the management of diffuse venous malformations...
Corseting: A new technique for the management of diffuse venous malformations...
 
More harm than benefit of perioperative dexamethasone on recovery following ...
More harm than benefit of perioperative  dexamethasone on recovery following ...More harm than benefit of perioperative  dexamethasone on recovery following ...
More harm than benefit of perioperative dexamethasone on recovery following ...
 
Validity of sentinel node biopsy in early oral and oropharyngeal carcinoma
Validity of sentinel node biopsy in early oral and oropharyngeal carcinomaValidity of sentinel node biopsy in early oral and oropharyngeal carcinoma
Validity of sentinel node biopsy in early oral and oropharyngeal carcinoma
 
Naso-orbital-ethmoid (NOE) fractures: Management principles, options and rec...
Naso-orbital-ethmoid (NOE) fractures: Management principles, options  and rec...Naso-orbital-ethmoid (NOE) fractures: Management principles, options  and rec...
Naso-orbital-ethmoid (NOE) fractures: Management principles, options and rec...
 
Temporomandibular joint ankylosis and its management
Temporomandibular joint ankylosis and its managementTemporomandibular joint ankylosis and its management
Temporomandibular joint ankylosis and its management
 
Maxillofacial space infections
Maxillofacial space infectionsMaxillofacial space infections
Maxillofacial space infections
 
Management of Impacted Third Molars
Management of Impacted Third MolarsManagement of Impacted Third Molars
Management of Impacted Third Molars
 
Paranasal sinus diseases and their management
Paranasal sinus diseases and their managementParanasal sinus diseases and their management
Paranasal sinus diseases and their management
 
Surgical Anatomy of Orbit
Surgical Anatomy of OrbitSurgical Anatomy of Orbit
Surgical Anatomy of Orbit
 
Surgical Anatomy of Temporomandibular Joint
Surgical Anatomy of Temporomandibular JointSurgical Anatomy of Temporomandibular Joint
Surgical Anatomy of Temporomandibular Joint
 
Surgical Anatomy of Salivary Glands and its Applied aspects
Surgical Anatomy of Salivary Glands and its Applied aspectsSurgical Anatomy of Salivary Glands and its Applied aspects
Surgical Anatomy of Salivary Glands and its Applied aspects
 
Evolution of oral and maxillofacial surgery
Evolution of oral and maxillofacial surgeryEvolution of oral and maxillofacial surgery
Evolution of oral and maxillofacial surgery
 
Diagnosis for edentulous patients
Diagnosis  for edentulous patientsDiagnosis  for edentulous patients
Diagnosis for edentulous patients
 
Implants : An Overview, Biomechanics & Treatment Planning
Implants : An Overview, Biomechanics & Treatment PlanningImplants : An Overview, Biomechanics & Treatment Planning
Implants : An Overview, Biomechanics & Treatment Planning
 
Oro-antral Fistula Poster
Oro-antral Fistula PosterOro-antral Fistula Poster
Oro-antral Fistula Poster
 
Orthodontic Study Model Analysis
Orthodontic Study Model Analysis Orthodontic Study Model Analysis
Orthodontic Study Model Analysis
 

Recently uploaded

CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 

Recently uploaded (20)

CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 

Oral mucosal lesions

  • 1. Oral Mucosal Lesions Presented by: Dibya Falgoon Sarkar (Dept. of Oral & Maxillofacial Surgery)
  • 2. Contents According to Burket oral mucosal lesions can be broadly classified into:  Red and white lesions  Pigmented lesions  Ulcerative, vesiculous and bullous lesions
  • 3. Red and white lesions  Infectious diseases: 1. Oral candidiasis 2. Oral hairy leukoplakia  Premalignant disorders: 1. Oral leukoplakia and erythroplakia 2. Oral submucous fibrosis  Immunopathologic diseases: 1. Oral lichen planus 2. Lichenoid reactions 3. Lupus erythematosus  Toxic reactions: 1. Tobacco pouch keratosis 2. Nicotinic stomatitis  Reactions to mechanical trauma: 1. Morsicatio 2. Frictional keratosis  Others: 1. Benign migratory glossitis 2. Leukoedema 3. White sponge nevus
  • 4. Oral Candidiasis (Thrush)  Usually caused by the normally present Candida albicans which becomes pathogenic because of altered host defense system. Systemic factors Local factors Diabetes , advanced systemic disease Use of dentures Xerostomia- Drugs or radiation Reduced vertical dimension Sjogren syndrome Overuse of antibiotic mouthrinses HIV infection & AIDS Lip-licking habit Systemic antibiotic, corticosteroid therapy
  • 5. Classification of oral candidiasis Primary oral candidiasis Secondary oral candidiasis Pseudomembranous HIV-AIDS Erythematous Familial chronic mucocutaneous disease Chronic plaque like DiGeorge syndrome Denture stomatitis Candidiasis endocrinopathy syndrome Angular chelitis Median rhomboid glossitis Hyperplastic
  • 6. Clinical presentations of oral candidiasis Angular cheilitis Median rhomboid glossitis Denture stomatitis HyperplasticPseudomembranous Erythematous
  • 7. Differential diagnosis  Leukoplakia- A leukoplakia will always remain adherent to the mucosa on rubbing. Candidiasis generally presents as pseudomembrane  Oral lichen planus- Generally presents as a reticular striae(Wickham’s striae) and is adherent on rubbling. Often presents with a burning sensation  Secondary syphilis- Generally associated with a primary chancre over site of inoculation  Chemical/ heat burns
  • 8. Diagnosis and treatment  Investigation- Tissue biopsy stained with PAS stain/ KOH mount, Fungal culture  Treatment-(according to Marx & Stern) 1. Mild forms: Clotrimazole oral solution 5ml 3-4times daily for 2 weeks 2. Chronic well established: Nystatin oral suspension (1lacU/ml, 5ml, 4 times daily) along with Clotrimazole troches (10mg, 5times daily) Refractory forms : Fluconazoles (100mg capsules once daily, 2 weeks) 3. Disseminated forms: Amphotericin B i.v. with D5 solution at a rate of 0.2-0.7 mg/kg/day. But it can lead to nephrotoxicity
  • 9. Oral hairy leukoplakia  Oral hairy leukoplakia is the second most common HIV-associated oral mucosal lesion  Associated with low CD4 T– lymphocyte count  Etiology- Epstein-Barr virus  Prevalance- Prior to HAART era it was around 25% In AIDS patients it is around 80%  Male> Female  Prevalent in smokers
  • 10. Clinical features, Diagnosis, Treatment  Site predilection- Lateral borders of tongue  Vertical white folds which cannot be scraped off  Asymptomatic condition  Diagnosis- Biopsy  Treatment- Antiviral medication
  • 11. Premalignant disorders  Premalignant lesions:  Oral leukoplakia  Erythroplakia  Reverse smoker’s palate  Premalignant conditions:  Oral submucous fibrosis  Oral lichen planus
  • 12. Oral leukoplakia  Oral leukoplakia is defined as a white plaque of questionable risk having excluded other known diseases or disorders that carry no risk for cancer  Etiology: Smoking, use of tobacco products, alcohol abuse which cause genetic changes in the oral mucosa  Prevalence- 2.6%  Mean age- 30-50 years  Sex predilection: Men > Women  Found in all oral sites. High-risk sites for malignant transformation: 1. Floor of Mouth 2. Lateral borders of tongue
  • 13. Types of oral leukoplakia Homogenous Nonhomogeneous White, well-demarcated plaque with identical pattern throughout the entire lesion • Presents as patches/plaques intermingled with red elements • Often termed as erythroleukoplakia/ speckled leukoplakia • Increased chances of malignant transformation
  • 14. Classification and Staging of Oral Leukoplakia Van der Waal et al., Journal of Oral oncology (2000)  L (size of leukoplakia)  L1: Size of single/ multiple leukoplakias together ≤ 2cm  L2: Size of single/ multiple leukoplakias together 2-4cm  L3: Size of single/ multiple leukoplakias together ≥4cm  P (pathology)  P0: No epithelial dysplasia  P1: Distinct epithelial dysplasia present  Staging:  Stage I: L1Po  Stage II: L2Po  Stage III: L3Po or L1/L2P1  Stage IV: L3P1
  • 15. Management of oral leukoplakia  Prognosis of leukoplakia patients is decided by: 1. Size of lesion 2. Homogeneous/non-homogeneous pattern  According to Burket, lesions <200sq.mm shows better prognosis  Cryotherapy can be used by it has limitations with depth control  Laser surgery and fulguration is widely used to eradicate leukoplakia and erythroplakia but tissue specimen for biopsy is not available.  According to Marx & Stern, leukoplakias which are graded as moderately dysplastic/ carcinoma in-situ are managed with surgical excision with 1cm margin regardless of size
  • 16. According to van der Waal et al Provisional clinical diagnosis of leukoplakia Elimination of possible cause (2-4 weeks observation) No possible cause (Definitive clinical diagnosis) Good response No response (Definitive clinical diagnosis) Biopsy Definable lesion • Management accordingly No definable lesion Dysplasia/No dysplasia Definable lesion • Management accordingly • Treatment/ Observation • Follow-up
  • 17. Proliferative verrucous leukoplakia  PVL is a field cancer phenomenon by which clinically normal-appearing oral mucosa slowly transforms through advancing stages of clinical leukoplakia, verrucous hyperplasia/ carcinoma, and then into invasive SCC  More common in older women(4:1)  Lower gingiva is a predilection site  Most patients(78%) are usually non smokers  High recurrence rate  High malignant potential  Increased correlation with oral Candida infection
  • 18. Diagnostic work-up & Management of PVL  Diagnosis mainly dependent on biopsy  Principles of PVL excisions differ from other leukoplakias: 1. Clear all peripheral margins 2. Areas of excision often cover large surfaces and thus split- thickness skin graft may be necessary after excision  Chemoprevention with fluconazole oral suspension and selenium(100microgram daily)  Literature shows bad prognosis in laser treated PVL cases
  • 19. Erythroplakia  The term erythroplakia is used analogously to designate lesions of oral mucosa that present as red areas and cannot be diagnosed as any other definable lesions (WHO, 1994)  Rare premalignant lesion with a prevalence of 0.09% (Acc. to Shafer & Waldron)  Age predilection: 6th-7th decades of life  Male: Female - 1:1  Site: Common in soft palate, buccal mucosa and floor-of-mouth  Aetiology: Same as those associated with squamous cell carcinoma
  • 20. Erythroplakia  Rare lesion with a malignant transformation rate of 26.3% (Acc. To Reddi & Shafer’s study)  Treatment : Observation for 1-2 weeks following elimination of irritants. Complete excision of the lesion with clear margins down to the submucosal level is the treatment of choice  Recurrence rate <5% (Acc. To Burket) Differential diagnosis of red lesions of oral mucosa: 1. Mycotic infections • Erythematous candidiasis • Denture stomatitis • Histoplasmosis 2. Bacterial infections • Tuberculosis 3. Mucosal diseases • Pemphigus, pemphigoid • Atrophic lichen planus • SLE 4. Others • Kaposi sarcoma • Haemangioma • Amelanotic melanoma
  • 21. Oral submucous fibrosis  Oral submucous fibrosis (OSF) is a collagen disorder commonly seen in the Indian subcontinent  First described by Schwartz in 1952  Pindborg et al. found a prevalence of 0.2~0.5% in India  Sex predilection: 5% prevalence in women & 2% in men  Areca nut (the fruit of the Areca catechu) commonly known as betel nut or supari, plays a crucial dual role in the etiology of OSMF  The attendant trismus is a result of juxtaepithelial hyalinization and secondary muscle involvement (i.e., muscular degeneration and fibrosis)  Malignant transformation has been noticed in 3-7.6% of cases
  • 22. Pathogenesis of OSMF Areca nut Arecoline (5-7%) Tannins (11-26%) Alkaloids (0.15%-0.6%) Fibroblast proliferation Stimulates collagen synthesis Collagen fibrils resistant to collagenase
  • 23. Clinical features and staging  One of the following characteristic must be present : 1. Palpable fibrous bands 2. Mucosal texture feels tough and leathery 3. Blanching of mucosa together with histologic features consistent with OSMF 4. Differential diagnosis: Scleroderma (Widening of PDL spaces present along with skin manifestations)
  • 24. According to Khanna-Andrade article Stage Clinical features Histology Group I • The common initial symptom was a burning sensation in the mouth. • Excessive salivation • The mouth opening was normal in all cases. • fine fibrillar collagen network was seen to be interspersed with marked edema. Blood vessels were dilated and congested • epithelium was essentially normal and nonkeratinized, with occasionally some hy- perplasia Group II • Interincisal openings of 26-35 mm. • The soft palate and faucial pillars were the areas primarily affected. The buccal mucosa ap- peared mottled and marble-like • Juxtaepithelial hyalini- zation was seen with the collagen present as thickened but separate bundles. • Flattening or shortening of the epithelial rete pegs was evident with varying degrees of keratinization
  • 25. Stage Clinical features Histology Group III: moderately advanced cases • Trismus was evident, with an inter- incisal opening of 15- 25 mm • Vertical fibrous bands could be palpated in the premolar area. • Juxtaepithelial hyalini- zation was present. Thickened collagen bundles were faintly discernible, separated by very slight, residual edema • Muscle fibers were seen to be interspersed with thickened and dense collagen fibers. Group IVa • Trismus was severe with an interincisal opening of 2-15 mm. • The fauces was thickened, shortened, and firm to palpation, with the tonsils compressed between the fibrosed pillars. • Shrunken uvula Collagen was hyalinized as a smooth sheet eliminating all evidence of individual bundles. Extensive fibrosis had obliterated the mucosal blood vessels and eliminated the melanocytes, a feature which explained the clinically observable loss of pigmentation Group IVb • advanced cases with premalignant and malignant changes
  • 26. Management of OSMF  Actively discourage patients from consuming areca nut and other chronic irritants such as hot and spicy foods  Well balanced diet with vitamin A & B-complex substitutes  Wherever possible we extract the third molars  Group I & II patients are put on conservative therapy and active physiotherapy  Group III & IV patients are treated by surgical intervention
  • 27. Conservative therapy in OSMF  Physical therapy: 1. Physical exercise 2. Microwave diathermy  Medical therapy:  Modulators of inflammation: 1. Corticosteroid 2. Interferon gamma 3. Placental extracts  Modulators for vascularity: 1. Pentoxiphylline 2. Nylidrin  Fibrinolysis: 1. Hyaluronidase 2. Collagenase  Nutritional support and antioxidants: 1. Beta-carotene 2. Lycopene 3. Vitamins  Ayurvedic treatment:  Turmeric  Tea pigments
  • 28. Conservative therapy in OSMF  Corticosteroid therapy: Submucosal injections of triamcinolone acetonide (40 mg) injected into the faucial pillars, retromolar area, and buccal mucosa. On average, a dose of 150-200 mg of local submucosal corticosteroid injection was given in divided doses at 10-day intervals for a period of 2-3 months.  Hyaluronidase(1500 I.U)- 0.5ml injected intralesionally twice a week for 10 days  Placental extract (Placentrex)- 2ml intralesional once a week along with iodine and vitamin B complex
  • 29. Surgical management  Rationale: Incision or surgical release of fibrous bands followed by forceful opening of mouth, and covering the surgical defects using various flaps and biosynthetic materials  In some cases we may need temporalis myotomy and bilateral coronoidectomy Extraoral flaps Intraoral flaps Microvascular Alloplasts Split thickness skin grafts Tongue flap ALT flap Collagen membrane Temporalis muscle/ fascia pedicled flap Palatal island flap Radial forearm free flap Artificial dermis Nasolabial flap Buccal fat pad Amnion graft
  • 30. Review of literature  Khanna & Andrade found disappointing results with split thickness skin grafting as they found marked shrinkage. They advocated bilateral palatal flaps.  Borle & Borle also encountered disappointing results with skin grafts. They used tongue flaps. But OSF patients show tongue involvement in 38% cases and post op morbidities are more with tongue flaps  Andrade et al. and Mehrotra et al. concluded that nasolabial flaps cannot extend adequately to cover the raw area and they also cause facial scars  Yeh et al. used pedicled buccal fat pad as it provided excellent function without deteriorating esthetics
  • 31. Verrucous carcinoma  Verrucous carcinoma is a distinct low grade variant of squamous cell carcinoma of oral cavity (According to Oral & maxillofacial surgery clinics- 2006)  First identified by Ackerman in 1948.  Rare tumor representing 3-4% of all oral carcinomas  Etiology- High incidence associated with use of tobacco products  16-51% of oral VCs are found in persons without tobacco habits  HPV is thought to be one of the causative agent
  • 32. Clinical presentation of verrucous carcinoma (VC)  True VCs are slow-growing, painless, broad-based wart-like papillary lesion  Site: buccal mucosa (60% cases), Gingiva (30%)  Male predilection seen  Age: Older than 50 years  Shows high propensity of local invasion rather than metastatic spread  Evidence of osseous invasion has been found  Inflammatory regional lymph nodes may be seen in some cases
  • 33. Treatment of Verrucous Carcinomas  Excision to a depth of full thickness of mucosa is the treatment of choice for oral VCs  According to Marx & Stern excisional depth: 1. Buccal mucosa: Upto buccinator fascia 2. Gingiva: Upto a supraperiosteal plane 3. Posterior and floor of mouth lesions are excised with a 2cm margin  Unlike squamous cell carcinomas VCs shows less radiosensitivity  Transformation of VCs into SCCs have been seen after radiation therapy  Recurrance rate: 26-57%
  • 34. Oral lichen planus (OLP)  Lichen planus is a T-cell mediated autoimmune interface disease in which the basal cell layer of mucosa and/or skin is attacked  Prevalence varies from 0.5-2.2%  Women more commonly affected  Mean age at the time of diagnosis: Approx. 55yrs  Premalignant condition  Malignant transformation potential 0.3-3%  Cutaneous lesions: 15% cases
  • 35. Clinical types of OLP  Reticular type:  Characterised by Wickham’s striae of lacy, white interlacing lines  Most common in buccal mucosa  Asymptomatic  Papular type: Clinically characterised by small white dots which intermingle with the reticular pattern  Plaque type: Homogeneous well-demarcated white plaque, asymptomatic
  • 36. Clinical types of OLP  Erosive/atrophic type:  Characterised by intense pain and mucosal inflammation  Presents as desquamative gingivitis  Ulcerative type:  Most disabling form of OLP  Fibrin coated ulcers surrounded by erythematous zones and white striae in periphery  Bullous type: Presents as bullous lesions surrounded by Wickham’s striae
  • 37. WHO diagnostic criteria for OLP (1978)  Clinical criteria 1. Presence of white papules, anular, reticular, plaque-like lesions, gray-white lines radiating from the papules 2. Presence of a lace-like network of slightly raised gray-white lines (reticular type) 3. Presence of atrophic lesions with/without erosions may also have bulla
  • 38. WHO diagnostic criteria for OLP (1978)  Histologic criteria 1. Presence of thickened orthokeratinised/ parakeratinised layers in sites that are normally keratinised 2. Presence of Civatte bodies in basal layer, epithelium and superficial part of connective tissue 3. Presence of a band-like zone of cellular infiltration in the superficial connective tissue, consisting mainly lymphocytes 4. Signs of liquefaction degeneration in basal layer
  • 39. Differential Diagnosis of OLP  Papules/ reticular components have to be present in order to establish correct clinical diagnosis  Differential diagnosis: 1. Discoid lupus erythematosus: Presents with hyperkeratinisation, striae abruptly terminate against a sharp demarcation 2. Pemphigus: Ulcerative type OLP have same presentation 3. Leukoplakia 4. Oral candidiasis
  • 40. Management of OLP  Reticular and plaque forms do not require treatment other than reassurance and follow-up  Milder forms of erosive type are managed with topical corticosteroids like clobetasol propionate/1% triamcinolone paste  Topical application of cyclosporine, tacrolimus and retinoids have been suggested as second-line of treatment  Systematic corticosteroid therapy with oral prednisolone may be used in extensive cases. But steroids have their side-effects Short-term effects Long term effects Hypertension, hyperglycaemia, infections, peptic ulcer, hypernatremia Muscle wasting, delayed wound healing, osteoporosis, cataracts
  • 41. Systemic corticosteroid therapy protocols Regimen I Regimen II Regimen IIIA Regimen IIIB Oral Prednisolone 1.5mg/kg/day for 2 weeks followed by tapering by 20mg/day each week until a 20mg /day dose is reached. The dose is followed for 1month followed by 10mg/day for 3 months, followed by 5mg every other day for 6 months Oral prednisolone 100- 120 mg/ day for 2 weeks after which the drug is stopped abruptly • Disadv: Frequent exacerbations Oral prednisolone 100- 120 mg/ day for 2 weeks • A tapering schedule reduces prednisone by 20mg/day each week until lowest possible level is reached without exacerbating the disease • Resistant pemphigus cases Oral prednisolone 100- 120 mg/ day for 2 weeks • A tapering schedule reduces prednisone by 20mg/day each week until a level is reached at which the disease is exacerbated • Combined with other immunosuppressive drugs to reduce side effects Preferred in Steven Johnson syndrome Useful in patients with life long steroid need Useful regimen in patients who cannot tolerate high dose steroids
  • 42. Drug-induced Lichenoid Reactions  Lichenoid reactions represent a family of lesions with different etiologies with a common clinical and histologic appearance  Etiology and pathogenesis: DILRs resemble a delayed hypersensitivity reaction where the drugs and their metabolites have the capability to act as haptens and trigger lichenoid reactions  Clinically appears similar to cutaneous LP and may be pruritic  DILRs are not life-threatening like Toxic epidermal necrolysis Common drugs ACE inhibitors Antimalarials Penicillin group Gold and heavy metals Sulphonamides OHA and OCPs Rifampicin
  • 43. Drug-induced Lichenoid Reactions  Management of drug-induced lichenoid reactions:  Discontinuation of the drug and symptomatic treatment with topical steroids  Patients must be cautioned of future use of same drugs
  • 44. Systemic Lupus Erythematous  SLE is an autoimmune disorder in which antigen- antibody complexes become entrapped in the capillaries of most organs. These complexes initiate the complement cascade and inflammation  Marked female predilection (90%) seen  Peak incidences between 20-40 years  Most characteristic signs- 1. Malar butterfly rash 2. Positive serum ANA test  Pathogenesis: Development of autoantibodies against native double stranded DNA. There marked depletion of complement proteins
  • 45. ACR diagnostic criteria for SLE 1. Serositis 2. Oral ulcers 3. Arthritis 4. Photosensitivity 5. Blood disorders- Lymphopenia, leukopenia, thrombocytopenia 6. Renal disorders- 0.5g/2h protonectin, cellular casts in urine 7. Anti-nuclear antibody positivity 8. Immunologic disorders 9. Neurologic disorders- seizure, psychosis 10. Malar rash 11. Discoid rash  At least 4 of these 11 criteria must be present before definitive diagnosis of SLE can be made along with a positive serum ANA test  Oral ulcers are red shallow ulcers commonly found in palate and marginal gingiva
  • 46. Differential diagnosis of SLE 1. Erythema multiforme 2. Discoid lupus erythematosus 3. Rheumatoid arthritis 4. Drug-induced lupus syndrome:  Males are equally affected  No neurologic/renal components  Anti- native DNA antibodies not present  Symptoms improve on stoppage of the drug
  • 47. Treatment of SLE  Mild forms of SLE are managed by supportive care. NSAIDS are given in mild flare-ups. Hydroxychloroquine 400mg orally is used to alleviate symptoms  Severe forms with multi-organ involvement are managed with systemic prednisone( systemic corticosteroid therapy IIIA & IIIB) Mycophenolate and cyclophosphamide may be added to these regimen to reduce the steroid requirement.
  • 48. Topical therapy for Oral lesions of SLE Drugs Direction for use 0.05% Clobetasol gel Place on affected area(s) 2 times/ day for 2 weeks Triamcinolone acetonide 5mg/ml Intralesional injection Topical clotrimazole troches (10mg) Dissolve in mouth 5 times/day for 10 days Chlorhexidine rinse (0.12%) Swish and spit 10ml twice daily until lesions resolve Adapted from Brennan et al.
  • 49. Discoid lupus erythematosus  Also known as chronic cutaneous lupus erythematosus  Immune-based disease primarily targets skin and to lesser degree, mucosa.  Lesions show similar characteristics and site predilection like that of SLE  Differential diagnosis: 1. SLE (No ANAs, hypocomplementia found) 2. Psoriasis 3. Skin TB 4. Leprosy  Treatment: Topical corticosteroids and preventive measures are taken in mild forms Severe forms are treated with systemic steroid regimens I & II
  • 50. Nicotinic stomatitis/ Smoker’s palate  Smoker’s palate initially presents as erythematous irritation and later transforms into a whitish palatal mucosa reflecting a hyperkeratosis  Reds dot can be observed representing inflamed orifices of accessory salivary gland ducts which can be enlarged and metplastic  Etiology and pathogenesis:  Seen in cigar and pipe smokers but not in cigarette smokers  Caused due to a combined effect of heat and tobacco products,  Not a premalignant lesion  Treatment: Cessation of smoking
  • 51. Leukoedema  Leukoedema is a white and veil- like alteration of the oral mucosa  Asymptomatic condition with no malignant potential  Etiology is not clear  Unlike leukoplakia, it is more diffuse and temporarily disappears on stretching  Requires no treatment
  • 52. White sponge nevus  Rare autosomal dominant disorder  Caused due to mutation of genes coding for epithelial keratin formation  Clinical features: • White lesions with elevated and irregular surface • Commonly seen in buccal mucosa  Histologically spinous epithelial cells show marked intracellular edema and are nondysplastic  Management: Benign, asymptomatic
  • 53. Benign Migratory Glossitis/ Geographic tongue  Annular lesion affecting the dorsum and margins of tongue  Unknown etiology, equal gender distribution  Prevalence 1-2.5% of all oral lesions  Clinical features:  Circumferentially migrating lesions with erythematous areas of depapillated tongue  Peripheral zones are white and elevated  Aggravates in periods of stress  Mostly asymptomatic  Self healing lesions  Symptomatic patients are given topical anesthetics
  • 54. Pigmented lesions of oral mucosa  Hairy tongue  Malignant melanoma  Haemochromatosis  Peutz-Jegher’s syndrome  Melasma  Amalgam tattoos  Endogenous pigmentation
  • 55. Hairy tongue  Etiology is unkown in most cases  Probable causes are: 1. Poor oral hygiene 2. Use of antibiotics/ immunosuppressant drugs 3. Therapeutic radiation 4. Excessive alcohol consumption 5. Smoking habits  Clinically presents as an impaired desquamation of the filiform papilla which leads to elongated papilla over dorsum of tongue  Pigmentation mainly comes from the oral microflora  Patients experience physical discomfort  Treatment: Use of tongue scrappers
  • 56. Malignant melanoma  Melanomas comprise of a rare group of aggressive, malignant neoplasms which are mainly found in skin of white people  Oral mucosal melanomas comprise of 0.2-8% of all melanomas diagnosed, commonly found in males more than 45 years age  Metastasis is predominantly via haematogenous routes  Site: Most common site is palate followed by the maxillary gingiva Nevus Melanoma Symmetry Asymmetry Borders regular Irregular borders Uniform color Color variegation Diameter static Diameter enlargement (>6mm) Color stable Evolution to darker pigment
  • 57. Clinical types of Oral Melanomas Superficial spreading • Most common between 40-60 years age • Initiallly looks like a nevus but later develop irregular border and odd shape • This radial growth pattern later changes Acral lentiginous • Rarely found in oral cavity • Characterised by a flat papular lesion with areas of nodularity (Vertical component Nodular melanoma • Most common between 50-70 years of age • Common in men • Shows vertical growth • Poor prognosis • Occasionally present as a flesh colored mass,amelanotic melanoma
  • 58. Breslow’s measurement of tumor thickness Thickness (mm) Risk of recurrence <0.76 Low risk 0.76-1.50 Low to intermediate risk 1.51-3.99 Intermediate to high risk >4.00 High risk Indicators of poor prognosis: • Surface ulceration • High mitotic index • Absence of lymphocyte infiltrations • Distant/ regional metastasis  Five year survival rate in patients with metastatic melanoma is <15%
  • 59. Treatment of oral melanomas  According to Marx & Stern wide local excision with 3-5cm margins is the treatment of choice. Neck dissection is to be done in cases with cervical lymph node metastasis  According to Burket adjuvant chemotherapy with alpha 2B interferon is approved in cutaneous melanoma cases with >4mm thickness  Use of adjuvant radiotherapy is a matter of debate  8 years survival rate is about 20%  Lungs is the most common site of metastasis followed by skin
  • 60. Oral Mucosal Lesions- Part II Presented by: Dibya Falgoon Sarkar (Dept. of Oral & Maxillofacial Surgery)
  • 61. Ulcerative, vesicular and bullous lesions Frequently used terms 1. Vesicles Small blisters containing clear fluid that are less than 1cm in diameter 2.Bullae Elevated blisters > 1cm in diameter 3. Erosions Red lesions caused by rupture of vesicles/bullae or by thinning of the skin 4. Ulcers A well-circumscribed, depressed lesion with an epithelial defect 5. Pustules Blisters containing yellowish purulent matter 6. Papules Lesions raised above skin/ mucosa < 1cm in diameter 7. Plaques Raised lesions > 1cm in diameter
  • 62.  We can broadly divide these type of lesions into: 1. Acute multiple ulcers: • Herpes simplex virus • Varicella-zoster • Erythema multiforme • Stevens- Johnson syndrome & Lyell disease • Necrotizing ulcerative gingivitis & periodontitis 2. Recurring oral ulcers: • Recurrent apthous stomatis • Behcet syndrome 3. Chronic multiple ulcers: • Pemphigus vulgaris • Pemphigoid 4.Single ulcers: mostly traumatic ulcers Ulcerative, vesicular and bullous lesions
  • 63. Herpes simplex virus infections (HSV)  HSV infections are caused by the Herpesviridae family. Spreads via airborne/ direct contact.  In general, infections above the waist are caused by HSV- 1 and below waist by HSV-2  Pathogenesis: Primary lesion is caused by inoculation of the virus in the oral mucosa, skin and eye with infected secretions  The virus then travels along the sensory neurons and causes a chronic, latent infection in sensory ganglion  Recurrent herpes occurs when HSV reactivates at latent sites and travels centripetally to the mucosa/ skin
  • 64. Clinical manifestations of HSV infection  Primary herpetic gingivostomatitis: • Caused mostly in children and young adults • Painful vesicular lesions on mucosal surfaces • Febrile, cervical lymphadenopathy • Lasts for 10 days and resolve on its own  Herpetic whitlow: • Occupational hazard among dentists • Contracted from the infected patients in the finger pads  Recurrent herpes: Seen over keratinised surfaces like palate and gingiva
  • 65. Diagnosis & management of HSV  Diagnosis: • Immunoslot testing detects circulating viral antibodies • Viral cultures and tissue biopsy are other alternatives  Treatment: • Self limiting disease which remains for 7-10 days • Topical 5% Acyclovir cream is helpful reduce symptoms • In extensive cases, oral Acyclovir 200mg five times for 10 days. Valacyclovir has more bioavailability Differential diagnosis 1.Erythema mutiforme 2.Erosive lichen planus 3. Apthous ulcer 4. Pempigus vulgaris
  • 66. Herpes Zoster virus infection  Primary infection with varicella zoster virus leads to varicella (chicken pox).  Reactivation of latent virus in the dorsal root ganglia of cranial nerves lead to herpes zoster infection/shingles.  Incidence: 1.5-3 cases per 1000 cases  More common in older individuals (>75 years)  Transmission usually by respiratory route.  Incubation period: 1-2 weeks  Postherpetic neuralgia is an uncommon sequelae seen in older individuals.
  • 67. Pathogenesis of Shingles and Postherpetic Neuralgia
  • 68. Clinical manifestations  Primary VZV infection mostly occurs in first two decades of life as maculopapular rash.  HZI of skin occurs in adults and start with prodromal symptoms like deep, burning skin sensation.  Within 2-4 days vesicles are seen in a dermatomal pattern unilaterally  Oral & maxillofacial manifestations: • Most commonly affects the ophthalmic div. of trigeminal nerve • Prodromal phase is characterised by burning mucosal pain • This is followed by appearance of clusters of 1- 5mm ulcers which heal within 14days
  • 69. Diagnosis & Management of HZV infections  Oral swab for viral isolation using cell culture is best way for confirming diagnosis. Real time PCR can also be used  Treatment:  Acyclovir (800mg five times a day)  Valacyclovir (1000mg three times a days)  Regimen shoud be started within 72hrs of onset  Postherpetic neuralgia: • First line of treatment is 5% lidocaine patch and topical capsaicin • Second line of treatment is with pregabalin, opioid analgesics and TCAs • Case reports suggest use of botulinum toxin in PHN  Vaccination of older adults reduces incidence of HZ infections.
  • 70. Ramsay-Hunt syndrome  Uncommon complication of Herpes zoster infection  Involves the geniculate ganglion  Clinical features:  Bell’s palsy, vesicles of external ear and loss of taste sensation in the anterior two thirds of tongue  Herpes zoster infections are more common in immunocompromised individuals
  • 71. Erythema multiforme (EM)  Acute, self-limited, inflammatory mucocutaneous disease.  Commonly manifests in skin, oral mucosa & genitalia  Represents hypersensitivity reactions to medications or infectious agents(e.g: Pneumonia, HSV, mycoplasma)  Two types: (Acc. To Burket) 1) Erythema multiforme minor- < 10% of total body skin 1) Erythema multiforme major- More extensive skin & mucosal involvement
  • 72. Clinical findings  EM generally affects individuals between 20-40 years  Prodromal phase is characterised with fever, malaise and headache, cough, rhinorrhea  Target/ iris lesions are pathognomonic of EM  Oral cavity lesions shows painful erythematous ulcerations, lips show haemorrhagic crusting
  • 73. Management of EM  Mild oral EM can be managed with systemic/ topical analgesics for pain and supportive care since the disease is self-limiting  More severe cases are manged with topical/ systemic corticosteroids  Acyclovir may be added if HSV infection is suspected  However, Marx & Stern contraindicates the use of steroids in EM minor as they are saying use of steroids increase the chance of infections
  • 74. Stevens-Johnson Syndrome  Also known as Erythema multiforme major  Life threatening and debilitating hypersensitivity  Characterised by an intense vasculitis due to a combined type III & IV hypersensitivity  Age: Less than 15 years  Clinical features: Triad of oral, ocular and genital lesions  SJS has an explosive onset and progress very rapidly  Treatment:  Emergency condition, requires intense supportive care  Fluid resuscitation is required to prevent dehydration  Systemic corticosteroids(IV methylprednisolone 500mg) along antibiotics coverage and immunosuppressive drugs  Silver diazine creams are applied locally, protection of eyes
  • 75. Necrotising ulcerative gingivitis and periodontitis  Represents an acute ulcerative- inflammatory condition of the gingiva and periodontium  Associated with polymicrobial infections  Strong association with immune suppression, diabetes, debilitation, smoking, stress, poor oral hygiene, local trauma, etc.  Etiology: Fusospirochaetal microorganisms  In presence of systemic illness NUG and NUP can progress into cancrum oris/ noma
  • 76. Seven stages of ANUG - Horning & Cohen Stages Stage I Necrosis of tip of papilla Stage II Necrosis of entire papilla Stage III Necrosis extending to marginal gingiva Stage IV Necrosis extending to attached gingiva Stage V Necrosis extending to labial & buccal mucosa Stage VI Necrosis exposing alveolar bone Stage VII Necrosis perforating skin of cheek
  • 77. Clinical features  Necrotising ulcerative gingivitis have a rapid onset.  First symptoms are excessive salivation, metallic taste, sensitivity of gingiva.  Disease rapidly progress into extremely painful punched-out ulcers which starts from interdental papilla.  Differential diagnosis: 1. Primary herpetic gingivostomatitis 2. Desquamative gingivitis 3. Mucous membrane pemphigoid  Laboratory tests: Gingival sulcular secretion culture.
  • 78. Treatment  Management is directed toward supportive care, pain control and identification of predisposing factors.  Definitive treatment consists of gentle debridement to remove plaque and debris under LA.  Hydrogen peroxide is used for killing anaerobic microbes along with chlorhexidine mouth wash.  Beta lactams and Metronidazole are antibiotics of choice  Patients must be tested for HIV  Once the acute phase is over we perform scaling and root planing for residual plaque removal.  Periodontal surgery is needed to correct the periodontal defects.
  • 79. Aphthous Stomatitis  Also known as canker sores  Pathogenesis: Believed to be due to an immune-based leukoclastic vasculitis Types Clinical findings Minor Most common, <1cm, lasts for 7-14 days, no scarring is seen, occurs over free oral mucosa Major >1cm, lasts for weeks, heals with scarring Herpetiform <1cm, >10 ulcers, dispersed widely over oral mucosa Severe Same as minor, but ulcers present continuously
  • 80. Treatment of aphthous ulcers  Minor aphthous ulcers are self-limiting and requires only reassurance of the patient.  Major aphthous ulcers are treated with a combination of antibiotics and systemic steroids.  Marx & Stern proposes three antibiotic regimens (2-6 months): 1. Erythromycin 250mg orally 4 times daily 2. Doxycycline 100mg orally once daily 3. Tetranydril elixir/ Magic mouth wash (Tetracycline 250mg+ 12.5 mg Diphenhydramine HCl per 5ml of Kaopectate  If these regimens fail we generally opt for systemic corticosteroid regimen with prednisone.
  • 81. Behcet syndrome  Triad of recurring oro-genital ulcers and eye involvement  Occurs in young adults, male predilection seen  Diagnostic criteria: a) Recurrent oral ulcers: Aphthous type ulcers which occur atleast 3 times in I year period b) Plus 2 of the following: 1. Eye lesions: Uveitis, retinal vasculitis and hypopyon 2. Skin lesions: Papulopustular genital lesions 3. Positive pathergy test  Treatment: Systemic corticosteroid regimen I or III with prednisone
  • 82. Pemphigus vulgaris (PV)  Pemphigus vulgaris falls in a group of autoimmune, potentially life- threatening disease.  Characterized by blisters and erosions of skin and mucous membranes due to intraepithelial acantholysis.  Etiology: Caused due to binding of IgG autoantibodies to desmoglein 3 & 1( transmembrane adhesion molecules) present on desmosomes.  Incidence: 0.1-0.5 cases per 1 lacs per year
  • 83. Clinical manifestations of PV  Classic lesion of PV consists of a thin-walled bulla arising on an otherwise normal skin/ mucosa.  These bullae rupture and continue to extend peripherally leaving areas of ulcerated mucosa and denuded skin ( Lutz sign).  Nikolsky sign: Pressure application on an apparently normal area of skin results in formation of a new lesion.  Oral lesions precede the lesions of skin  Diagnosis: 1. Direct immunofluorescence 2. Indirect immunofluorescence 3. Biopsies are best done on intact vesicles < 24hrs old
  • 84. Differential diagnosis of PV 1. Herpes simplex virus infections: Affects young children, acute onset 2. Erythema multiforme: Acute nature, patient gives history of taking medications in most cases, target lesions are seen 3. Recurrent aphthous stomatitis: Aphthous ulcers are round and symmetrical. They tend to heal and recur. But in pemphigus, the same lesions continue to extend peripherally in a chronic nature. 4. Mucous membrane pemphigoid: Distinguished by indirect immunofluorescence
  • 85. Treatment of Pemphigus vulgaris  Most important aspect is early diagnosis of the disease when lower doses of medication can be used for shorter periods of time to control the disease.  High doses of systemic corticosteroids (Prednisone) are given in dosages of 1-2mg/kg/day  Adjuvant therapy to reduce the side-effects of steroids include azathioprine, mycophenolate, etc.  Rituximab is presently used though there are reports of high infection rates.
  • 86. Mucous Membrane Pemphigoid  Chronic autoimmune subepithelial disease which primarily affects mucous membranes  Age: More than 50 years  Female:Male : 2:1  Etiology: Primary lesion of MMP occurs when autoantibodies directed against proteins in the basement membrane zone cause a subepithelial split and vesicle formation.  Conjuctiva is the second most common site after oral cavity.  Corneal damage, symblepheron and blindness are common ocular manifestations.  Desquamative gingivitis is the most common oral lesion
  • 87. Treatment of mucous membrane pemphigoid  Patients with mild oral disease are treated with topical and intralesional steroids  Ophthalmologists must be consulted for the management of ocular manifestation  Systemic steroid therapy regimen I & III are used in severe cases Cicatricial pemphigoid with symblepheron
  • 88. Management of patients on Corticosteroid therapy who require Major surgery  Patients who regularly take corticosteroids develop adrenal insufficiency due to depression of HPA axis.  According to Hupp, Ellis & Tucker: 1. If the pateint is currently taking steroids:  Use anxiety-reduction protocol.  Monitoring of vitals before, during and after surgery.  Instruct patient to double usual daily dose on day before, day of, and day after surgery.  On second post op day advise the patient to return to usual dose.
  • 89. Management of patients on Corticosteroid therapy who require Major surgery  According to Hupp, Ellis & Tucker: 2. If the patient is not currently taking steroids but has received atleast 20mg of hydrocortisone or equivalent for >2 weeks in past one year,  Use anxiety-reduction protocol  Monitoring of vitals before, during and after surgery.  Instruct the patient to take 60mg hydrocortisone on the day before and the morning of surgery  On the first 2 post op days, the dose should be dropped to 40mg and dropped to 20mg for 3 days thereafter. The clinician can cease administration of supplemental steroids 6 days after surgery.
  • 90. References  Burket’s Oral Medicine  Oral & Maxillofacial Pathology – Marx & Stern  Oral & Maxillofacial Surgery Clinics of North America (2006 issue)  Van der Waal et al., Journal of Oral oncology (2000)  Khanna, Andrade: Oral submucous fibrosis : A new concept of management: Report of 100 cases; IJOMS 1995

Editor's Notes

  1. Lesions present with a definitive borders which are present 0.1-0.2mm below the level of surrounding mucosa unlike that of an atrophic lichen planus which has no definitive borders
  2. Macules: Lesions that are flush with the adjacent mucosa and that are noticeable bcoz of their color difference Nodules: These lesions are present within the dermis/ mucosa
  3. Fusobacterium necrophorum play an important role in noma by producing dermonecrotic toxin
  4. Also use of proper antibiotics, prevention of peptic ulcer, osteoporosis
  5. In minor surgery like dental extractions only use anxiety-reduction protocol